Conclusion
While the amount of knowledge on rhinitis and allergic rhinitis in
children is continuously increasing, novel approaches mostly deriving
from adult populations, have the potential of improving outcomes in
children. Considering that blinded randomized trials are more difficult
to perform in pediatrics, real-life approaches may be used to confirm
the usefulness of these proposals[138]. It is probable that, as in
the case of pediatric asthma [139], prevention studies and
interventions on the natural history of rhinitis and/or respiratory
allergy as a whole, are the highest priority for research and health
policy.
REFERENCES
1. Samoliński, B., et al., Prevention and control of childhood
asthma and allergy in the EU from the public health point of view:
Polish Presidency of the European Union. Allergy, 2012. 67 (6):
p. 726-31.
2. Georgountzou, A., et al., Age-dependent changes in circulating
leukocytes from birth to adulthood in healthy and atopic subjects.Allergy, 2019. 74 (S106): p. 139-139.
3. Fokkens, W.J., et al., European Position Paper on
Rhinosinusitis and Nasal Polyps 2020. Rhinology, 2020.58 (Suppl S29): p. 1-464.
4. Georgountzou, A. and N.G. Papadopoulos, Postnatal Innate Immune
Development: From Birth to Adulthood. Front Immunol, 2017. 8 :
p. 957.
5. Zhong, H., et al., Increased innate type 2 immune response in
house dust mite-allergic patients with allergic rhinitis. Clin Immunol,
2017. 183 : p. 293-299.
6. Hammad, H. and B.N. Lambrecht, Barrier Epithelial Cells and the
Control of Type 2 Immunity. Immunity, 2015. 43 (1): p. 29-40.
7. Divekar, R. and H. Kita, Recent advances in epithelium-derived
cytokines (IL-33, IL-25, and thymic stromal lymphopoietin) and allergic
inflammation. Curr Opin Allergy Clin Immunol, 2015. 15 (1): p.
98-103.
8. Wise, S.K., et al., International Consensus Statement on
Allergy and Rhinology: Allergic Rhinitis. Int Forum Allergy Rhinol,
2018. 8 (2): p. 108-352.
9. Eifan, A.O. and S.R. Durham, Pathogenesis of rhinitis. Clin
Exp Allergy, 2016. 46 (9): p. 1139-51.
10. Peng, Y.Q., et al., Effects of myeloid and plasmacytoid
dendritic cells on ILC2s in patients with allergic rhinitis. J Allergy
Clin Immunol, 2020. 145 (3): p. 855-867 e8.
11. Coomes, S.M., et al., CD4(+) Th2 cells are directly regulated
by IL-10 during allergic airway inflammation. Mucosal Immunol, 2017.10 (1): p. 150-161.
12. Taka, S., et al., MicroRNAs in Asthma and Respiratory
Infections: Identifying Common Pathways. Allergy Asthma Immunol Res,
2020. 12 (1): p. 4-23.
13. Zeng, Q., et al., MicroRNA-181a and microRNA-155 are involved
in the regulation of the differentiation and function of regulatory T
cells in allergic rhinitis children. Pediatr Allergy Immunol, 2019.30 (4): p. 434-442.
14. Yang, Q., et al., Infiltration pattern of gammadelta T cells
and its association with local inflammatory response in the nasal mucosa
of patients with allergic rhinitis. Int Forum Allergy Rhinol, 2019.9 (11): p. 1318-1326.
15. Eifan, A.O., et al., Reduced T-bet in addition to enhanced
STAT6 and GATA3 expressing T cells contribute to human allergen-induced
late responses. Clin Exp Allergy, 2012. 42 (6): p. 891-900.
16. Jiao, W.E., et al., Notch Signaling Promotes Development of
Allergic Rhinitis by Suppressing Foxp3 Expression and Treg Cell
Differentiation. Int Arch Allergy Immunol, 2019. 178 (1): p.
33-44.
17. Yao, Y., et al., CD23 expression on switched memory B cells
bridges T-B cell interaction in allergic rhinitis. Allergy, 2020.
18. Wirz, O.F., et al., Comparison of regulatory B cells in asthma
and allergic rhinitis. Allergy, 2019. 74 (4): p. 815-818.
19. Arebro, J., et al., A possible role for neutrophils in
allergic rhinitis revealed after cellular subclassification. Sci Rep,
2017. 7 : p. 43568.
20. Polak, D., et al., A novel role for neutrophils in
IgE-mediated allergy: Evidence for antigen presentation in late-phase
reactions. J Allergy Clin Immunol, 2019. 143 (3): p. 1143-1152
e4.
21. Kota, A., et al., Autophagy and airway fibrosis: Is there a
link? F1000Res, 2017. 6 : p. 409.
22. Li, J. and Y. Li, Autophagy is involved in allergic rhinitis
by inducing airway remodeling. Int Forum Allergy Rhinol, 2019.9 (11): p. 1346-1351.
23. Papadopoulos, N.G., et al., Phenotypes and endotypes of
rhinitis and their impact on management: a PRACTALL report. Allergy,
2015. 70 (5): p. 474-94.
24. Papadopoulos, N.G. and G.V. Guibas, Rhinitis Subtypes,
Endotypes, and Definitions. Immunol Allergy Clin North Am, 2016.36 (2): p. 215-33.
25. Patel, V.A. and M.M. Carr, Congenital nasal obstruction in
infants: A retrospective study and literature review. Int J Pediatr
Otorhinolaryngol, 2017. 99 : p. 78-84.
26. Poddighe, D., et al., Non-allergic rhinitis in children:
Epidemiological aspects, pathological features, diagnostic methodology
and clinical management. World J Methodol, 2016. 6 (4): p.
200-213.
27. Lee, K.S., et al., Local Immune Responses in Children and
Adults with Allergic and Nonallergic Rhinitis. PLoS One, 2016.11 (6): p. e0156979.
28. Segboer, C.L., et al., Endotyping of non-allergic, allergic
and mixed rhinitis patients using a broad panel of biomarkers in nasal
secretions. PLoS One, 2018. 13 (7): p. e0200366.
29. Tsilochristou, O., et al., Detection of local allergic
rhinitis in children with chronic, difficult-to-treat, non-allergic
rhinitis using multiple nasal provocation tests. Pediatr Allergy
Immunol, 2019. 30 (3): p. 296-304.
30. Colavita, L., et al., Local Allergic Rhinitis in Pediatric
Patients: Is IgE Dosage in Nasal Lavage Fluid a Useful Diagnostic Method
in Children? Int J Mol Cell Med, 2017. 6 (3): p. 174-182.
31. Zicari, A.M., et al., Local allergic rhinitis in children:
Novel diagnostic features and potential biomarkers. Am J Rhinol
Allergy, 2016. 30 (5): p. 329-34.
32. Campo, P., et al., Local allergic rhinitis: Implications for
management. Clin Exp Allergy, 2019. 49 (1): p. 6-16.
33. NE, E.L. and M.W. El-Anwar, Assessment of Nasal Immunoglobulin
E Level in Atopic and Non-atopic Rhinitis Patients: A Tool for Diagnosis
of Local Allergic Rhinitis. Egypt J Immunol, 2016. 23 (1): p.
45-56.
34. Van Gerven, L., B. Steelant, and P.W. Hellings, Nasal
hyperreactivity in rhinitis: A diagnostic and therapeutic challenge.Allergy, 2018. 73 (9): p. 1784-1791.
35. Giannico, R., et al., Non-specific nasal provocation in
children with chronic allergic rhinitis. J Investig Allergol Clin
Immunol, 1996. 6 (2): p. 110-6.
36. Lluch-Bernal, M., et al., Nasal Hyperreactivity: Nonspecific
Nasal Provocation Tests. Review by the Rhinoconjunctivitis Committee of
the Spanish Society of Allergy and Clinical Immunology. J Investig
Allergol Clin Immunol, 2015. 25 (6): p. 396-407.
37. Baroody, F.M., Nonallergic Rhinitis: Mechanism of Action.Immunol Allergy Clin North Am, 2016. 36 (2): p. 279-87.
38. Van Gerven, L., et al., Capsaicin treatment reduces nasal
hyperreactivity and transient receptor potential cation channel
subfamily V, receptor 1 (TRPV1) overexpression in patients with
idiopathic rhinitis. J Allergy Clin Immunol, 2014. 133 (5): p.
1332-9, 1339 e1-3.
39. Steelant, B., et al., Impaired barrier function in patients
with house dust mite-induced allergic rhinitis is accompanied by
decreased occludin and zonula occludens-1 expression. J Allergy Clin
Immunol, 2016. 137 (4): p. 1043-1053 e5.
40. Hamed, A., et al., Nasal IgE production in allergic rhinitis:
Impact of rhinovirus infection. Clin Exp Allergy, 2019. 49 (6):
p. 847-852.
41. Doulaptsi, M., et al., Prevalence and impact of nasal
hyperreactivity in chronic rhinosinusitis. Allergy, 2020.75 (7): p. 1768-1771.
42. Bousquet, J., et al., Are allergic multimorbidities and IgE
polysensitization associated with the persistence or re-occurrence of
foetal type 2 signalling? The MeDALL hypothesis. Allergy, 2015.70 (9): p. 1062-78.
43. Anto, J.M., et al., Mechanisms of the Development of Allergy
(MeDALL): Introducing novel concepts in allergy phenotypes. J Allergy
Clin Immunol, 2017. 139 (2): p. 388-399.
44. Pinart, M., et al., Comorbidity of eczema, rhinitis, and
asthma in IgE-sensitised and non-IgE-sensitised children in MeDALL: a
population-based cohort study. Lancet Respir Med, 2014. 2 (2):
p. 131-40.
45. Bousquet, J., et al., MeDALL (Mechanisms of the Development of
ALLergy): an integrated approach from phenotypes to systems medicine.Allergy, 2011. 66 (5): p. 596-604.
46. Blondal, V., et al., Study of atopic multimorbidity in
subjects with rhinitis using multiplex allergen component analysis.Clin Transl Allergy, 2020. 10 : p. 6.
47. Gabet, S., et al., Early polysensitization is associated with
allergic multimorbidity in PARIS birth cohort infants. Pediatr Allergy
Immunol, 2016. 27 (8): p. 831-837.
48. Ballardini, N., et al., IgE antibodies in relation to
prevalence and multimorbidity of eczema, asthma, and rhinitis from birth
to adolescence. Allergy, 2016. 71 (3): p. 342-9.
49. Aguilar, D., et al., Computational analysis of multimorbidity
between asthma, eczema and rhinitis. PLoS One, 2017. 12 (6): p.
e0179125.
50. Aguilar, D., et al., Understanding allergic multimorbidity
within the non-eosinophilic interactome. PLoS One, 2019.14 (11): p. e0224448.
51. Ferreira, M.A., et al., Shared genetic origin of asthma, hay
fever and eczema elucidates allergic disease biology. Nat Genet, 2017.49 (12): p. 1752-1757.
52. Demenais, F., et al., Multiancestry association study
identifies new asthma risk loci that colocalize with immune-cell
enhancer marks. Nat Genet, 2018. 50 (1): p. 42-53.
53. Lau, S., et al., Allergy and atopy from infancy to adulthood:
Messages from the German birth cohort MAS. Ann Allergy Asthma Immunol,
2019. 122 (1): p. 25-32.
54. Toppila-Salmi, S., et al., Risk of adult-onset asthma
increases with the number of allergic multimorbidities and decreases
with age. Allergy, 2019. 74 (12): p. 2406-2416.
55. Hohmann, C., et al., Sex-specific incidence of asthma,
rhinitis and respiratory multimorbidity before and after puberty onset:
individual participant meta-analysis of five birth cohorts collaborating
in MeDALL. BMJ Open Respir Res, 2019. 6 (1): p. e000460.
56. Jantunen, J., et al., Multimorbidity in Asthma, Allergic
Conditions and COPD Increase Disease Severity, Drug Use and Costs: The
Finnish Pharmacy Survey. Int Arch Allergy Immunol, 2019.179 (4): p. 273-280.
57. Bousquet, J., et al., Allergic Rhinitis and its Impact on
Asthma (ARIA) 2008 update (in collaboration with the World Health
Organization, GA(2)LEN and AllerGen). Allergy, 2008. 63 Suppl
86 : p. 8-160.
58. Demoly, P., et al., Assessment of disease control in allergic
rhinitis. Clin Transl Allergy, 2013. 3 (1): p. 7.
59. Bousquet, J., et al., Next-generation Allergic Rhinitis and
Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on
Grading of Recommendations Assessment, Development and Evaluation
(GRADE) and real-world evidence. J Allergy Clin Immunol, 2020.145 (1): p. 70-80 e3.
60. Demoly, P., et al., Validation of a self-questionnaire for
assessing the control of allergic rhinitis. Clin Exp Allergy, 2011.41 (6): p. 860-8.
61. Linhares, D.V., et al., Validation of control of allergic
rhinitis and asthma test for children (CARATKids)–a prospective
multicenter study. Pediatr Allergy Immunol, 2014. 25 (2): p.
173-9.
62. Emons, J.A., et al., Use of the Control of Allergic Rhinitis
and Asthma Test (CARATkids) in children and adolescents: Validation in
Dutch. Pediatr Allergy Immunol, 2017. 28 (2): p. 185-190.
63. Meltzer, E.O., et al., Reliability, validity, and
responsiveness of the Rhinitis Control Assessment Test in patients with
rhinitis. J Allergy Clin Immunol, 2013. 131 (2): p. 379-86.
64. Morais-Almeida, M., et al., Prevalence and classification of
rhinitis in preschool children in Portugal: a nationwide study.Allergy, 2013. 68 (10): p. 1278-88.
65. Bousquet, J., et al., ARIA 2016: Care pathways implementing
emerging technologies for predictive medicine in rhinitis and asthma
across the life cycle. Clin Transl Allergy, 2016. 6 : p. 47.
66. Bousquet, J., et al., MACVIA clinical decision algorithm in
adolescents and adults with allergic rhinitis. J Allergy Clin Immunol,
2016. 138 (2): p. 367-374 e2.
67. World Health Organization (WHO). Digital Health . 2018 April
12,2020]; Available from:https://apps.who.int/gb/ebwha/pdf_files/WHA71/A71_R7-en.pdf?ua=1.
68. World Health Organization (WHO). Recommendations on digital
interventions for health system strengthening . 2019 [cited 2020 April
20]; Available from:https://apps.who.int/iris/bitstream/handle/10665/311941/9789241550505-eng.pdf?ua=1.
69. Gu, T. Newzoo’s Global Mobile Market Report: Insights into the
World’s 3.2 Billion Smartphone Users, the Devices They Use & the Mobile
Games They Play . 2019; Available from:https://newzoo.com/insights/articles/newzoos-global-mobile-market-report-insights-into-the-worlds-3-2-billion-smartphone-users-the-devices-they-use-the-mobile-games-they-play/.
70. Schaeffer, K. Most U.S. teens who use cellphones do it to pass
time, connect with others, learn new things . 2019 [cited 2020 April
21, 2020]; Available from:https://pewresearch-org-preprod.go-vip.co/fact-tank/2019/08/23/most-u-s-teens-who-use-cellphones-do-it-to-pass-time-connect-with-others-learn-new-things/.
71. Bousquet, J., et al., Allergic Rhinitis and its Impact on
Asthma (ARIA) Phase 4 (2018): Change management in allergic rhinitis and
asthma multimorbidity using mobile technology. J Allergy Clin Immunol,
2019. 143 (3): p. 864-879.
72. Gray, W.N., et al., Medication adherence in pediatric asthma:
A systematic review of the literature. Pediatr Pulmonol, 2018.53 (5): p. 668-684.
73. Pizzulli, A., et al., The impact of telemonitoring on
adherence to nasal corticosteroid treatment in children with seasonal
allergic rhinoconjunctivitis. Clin Exp Allergy, 2014. 44 (10):
p. 1246-54.
74. Matricardi, P.M., et al., The role of mobile health
technologies in allergy care: An EAACI position paper. Allergy, 2020.75 (2): p. 259-272.
75. Bastl, K., U. Berger, and M. Kmenta, Evaluation of Pollen Apps
Forecasts: The Need for Quality Control in an eHealth Service. J Med
Internet Res, 2017. 19 (5): p. e152.
76. European Council, Regulation 2017/745 of the European
Parliament and of the Council of 5 April 2017 on medical devices.Official Journal of the European Union, 2017. 60 : p. 1-175.
77. U.S. Food & Drug Administration (FDA). Policy for Device
Software Functions and Mobile Medical Applications . 2019 [cited 2020
April 21]; Available from:https://www.fda.gov/media/80958/download.
78. European Council, Regulation 2016/679 of the European
Parliament and of the Council of 27 April 2016 on the protection of
natural persons with regard to the processing of personal data and on
the free movement of such data, and repealing Directive 95/46/EC
(General Data Protection Regulation). Official Journal of the European
Union, 2016. 59 : p. 1-88.
79. Bousquet, J., et al., Mobile Technology in Allergic Rhinitis:
Evolution in Management or Revolution in Health and Care? J Allergy
Clin Immunol Pract, 2019. 7 (8): p. 2511-2523.
80. Caimmi, D., et al., Validation of the MASK-rhinitis visual
analogue scale on smartphone screens to assess allergic rhinitis
control. Clin Exp Allergy, 2017. 47 (12): p. 1526-1533.
81. Bousquet, J., et al., MASK 2017: ARIA digitally-enabled,
integrated, person-centred care for rhinitis and asthma multimorbidity
using real-world-evidence. Clin Transl Allergy, 2018. 8 : p.
45.
82. Sleurs, K., et al., Mobile health tools for the management of
chronic respiratory diseases. Allergy, 2019. 74 (7): p.
1292-1306.
83. Courbis, A.L., et al., Electronic Clinical Decision Support
System for allergic rhinitis management: MASK e-CDSS. Clin Exp Allergy,
2018. 48 (12): p. 1640-1653.
84. L., K., et al., Allergymap: A Hybrid mHealth Mobile
Crowdsensing System for Allergic Diseases Epidemiology : a
multidisciplinary case study , in 2018 IEEE International
Conference on Pervasive Computing and Communications Workshops (Percom
Workshops) . 2018, IEEE: Athens. p. 597-602.
85. Roberts, G., et al., Paediatric rhinitis: position paper of
the European Academy of Allergy and Clinical Immunology. Allergy, 2013.68 (9): p. 1102-16.
86. Klimek, L., et al., Visual analogue scales (VAS): Measuring
instruments for the documentation of symptoms and therapy monitoring in
cases of allergic rhinitis in everyday health care: Position Paper of
the German Society of Allergology (AeDA) and the German Society of
Allergy and Clinical Immunology (DGAKI), ENT Section, in collaboration
with the working group on Clinical Immunology, Allergology and
Environmental Medicine of the German Society of Otorhinolaryngology,
Head and Neck Surgery (DGHNOKHC). Allergo J Int, 2017. 26 (1):
p. 16-24.
87. Roche, N., et al., The importance of real-life research in
respiratory medicine: manifesto of the Respiratory Effectiveness Group:
Endorsed by the International Primary Care Respiratory Group and the
World Allergy Organization. Eur Respir J, 2019. 54 (3).
88. Katotomichelakis, M., et al., Alternaria and Cladosporium
calendar of Western Thrace: Relationship with allergic rhinitis
symptoms. Laryngoscope, 2016. 126 (2): p. E51-6.
89. Cox, L., Approach to Patients with Allergic Rhinitis: Testing
and Treatment. Med Clin North Am, 2020. 104 (1): p. 77-94.
90. Phipatanakul, W., et al., Environmental assessment and
exposure reduction of rodents: a practice parameter. Ann Allergy Asthma
Immunol, 2012. 109 (6): p. 375-87.
91. Murray, C.S., et al., Preventing Severe Asthma Exacerbations
in Children. A Randomized Trial of Mite-Impermeable Bedcovers. Am J
Respir Crit Care Med, 2017. 196 (2): p. 150-158.
92. Custovic, A., C.S. Murray, and A. Simpson, Dust-mite inducing
asthma: what advice can be given to patients? Expert Rev Respir Med,
2019. 13 (10): p. 929-936.
93. Scadding, G.K., et al., BSACI guideline for the diagnosis and
management of allergic and non-allergic rhinitis (Revised Edition 2017;
First edition 2007). Clin Exp Allergy, 2017. 47 (7): p.
856-889.
94. Nurmatov, U.B., et al., Volatile organic compounds and risk of
asthma and allergy: a systematic review. Eur Respir Rev, 2015.24 (135): p. 92-101.
95. Burte, E., et al., Association between air pollution and
rhinitis incidence in two European cohorts. Environ Int, 2018.115 : p. 257-266.
96. Zhao, F., et al., Common ragweed (Ambrosia artemisiifolia L.):
allergenicity and molecular characterization of pollen after plant
exposure to elevated NO2. Plant Cell Environ, 2016. 39 (1): p.
147-64.
97. Eguiluz-Gracia, I., et al., The need for clean air: The way
air pollution and climate change affect allergic rhinitis and asthma.Allergy, 2020.
98. Motola, D., et al., Safety profile of H1-antihistamines in
pediatrics: an analysis based on data from VigiBase. Pharmacoepidemiol
Drug Saf, 2017. 26 (10): p. 1164-1171.
99. Church, M.K., Allergy, Histamine and Antihistamines. Handb
Exp Pharmacol, 2017. 241 : p. 321-331.
100. Cataldi, M., et al., Cardiac safety of second-generation H1
-antihistamines when updosed in chronic spontaneous urticaria. Clin Exp
Allergy, 2019. 49 (12): p. 1615-1623.
101. Horak, F. and U.P. Zieglmayer, Azelastine nasal spray for the
treatment of allergic and nonallergic rhinitis. Expert Rev Clin
Immunol, 2009. 5 (6): p. 659-69.
102. Schumacher, S., et al., Unique immunomodulatory effects of
azelastine on dendritic cells in vitro. Naunyn Schmiedebergs Arch
Pharmacol, 2014. 387 (11): p. 1091-9.
103. Karatzanis, A., et al., Contemporary Use of Corticosteroids
in Rhinology. Curr Allergy Asthma Rep, 2017. 17 (2): p. 11.
104. Segboer, C., et al., Intranasal corticosteroids for
non-allergic rhinitis. Cochrane Database Syst Rev, 2019.2019 (11).
105. Bensch, G.W., Safety of intranasal corticosteroids. Ann
Allergy Asthma Immunol, 2016. 117 (6): p. 601-605.
106. Hicks, A. and M. Egan, On-Demand Intranasal Corticosteroids
for Treatment of Seasonal Allergic Rhinitis in Children. J Allergy Clin
Immunol Pract, 2018. 6 (4): p. 1430-1431.
107. Bousquet, J., et al., Intranasal corticosteroids in allergic
rhinitis in COVID-19 infected patients: An ARIA-EAACI statement.Allergy, 2020.
108. Berger, W., et al., Efficacy of MP-AzeFlu in children with
seasonal allergic rhinitis: Importance of paediatric symptom
assessment. Pediatr Allergy Immunol, 2016. 27 (2): p. 126-33.
109. Debbaneh, P.M., et al., Intranasal Azelastine and Fluticasone
as Combination Therapy for Allergic Rhinitis: Systematic Review and
Meta-analysis. Otolaryngol Head Neck Surg, 2019. 161 (3): p.
412-418.
110. Berger, W., et al., Safety of a novel intranasal formulation
of azelastine hydrochloride and fluticasone propionate in children: A
randomized clinical trial. Allergy Asthma Proc, 2018. 39 (2):
p. 110-116.
111. http://cisn.co/2AD11JK.,Dymista approved in children 6 to 11 years of age with seasonal
allergic rhinitis . Accessed 12 Oct 2018.
112. Schuler Iv, C.F. and J.M. Montejo, Allergic Rhinitis in
Children and Adolescents. Pediatr Clin North Am, 2019. 66 (5):
p. 981-993.
113. (FDA), U.S.F.D.A. FDA requires Boxed Warning about serious
mental health side effects for asthma and allergy drug montelukast
(Singulair); advises restricting use for allergic rhinitis . 2020
[cited 2020 03 Sep]; Available from:https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-boxed-warning-about-serious-mental-health-side-effects-asthma-and-allergy-drug.
114. Licari, A., et al., Current and emerging biologic therapies
for allergic rhinitis and chronic rhinosinusitis. Expert Opin Biol
Ther, 2020: p. 1-11.
115. Humbert, M., et al., IgE-Mediated Multimorbidities in
Allergic Asthma and the Potential for Omalizumab Therapy. J Allergy
Clin Immunol Pract, 2019. 7 (5): p. 1418-1429.
116. Yu, C., et al., Clinical Efficacy and Safety of Omalizumab in
the Treatment of Allergic Rhinitis: A Systematic Review and
Meta-analysis of Randomized Clinical Trials. Am J Rhinol Allergy, 2020.34 (2): p. 196-208.
117. Kopp, M.V., et al., Combination of omalizumab and specific
immunotherapy is superior to immunotherapy in patients with seasonal
allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma.Clin Exp Allergy, 2009. 39 (2): p. 271-9.
118. Castro, M., et al., Dupilumab Efficacy and Safety in
Moderate-to-Severe Uncontrolled Asthma. N Engl J Med, 2018.378 (26): p. 2486-2496.
119. Weinstein, S.F., et al., Efficacy and safety of dupilumab in
perennial allergic rhinitis and comorbid asthma. J Allergy Clin
Immunol, 2018. 142 (1): p. 171-177 e1.
120. Dupilumab As An Adjunct For Subcutaneous Grass
Immunotherapy. ClinicalTrials.gov identifier:NCT03558997.https://ClinicalTrials.gov/show/NCT03558997.
Updated May 28, 2020. Accessed September 3, 2020.
121. Head, K., et al., Saline irrigation for allergic rhinitis.Cochrane Database Syst Rev, 2018. 6 : p. CD012597.
122. Mitsias, D.I., et al., Effect of nasal irrigation on allergic
rhinitis control in children; complementarity between CARAT and MASK
outcomes. Clin Transl Allergy, 2020. 10 : p. 9.
123. Kenney, P., et al., Preventive effect of nasal filters on
allergic rhinitis: A randomized, double-blind, placebo-controlled
crossover park study. J Allergy Clin Immunol, 2015. 136 (6): p.
1566-1572 e5.
124. Wu, A.W., et al., Alternative therapies for sinusitis and
rhinitis: a systematic review utilizing a modified Delphi method. Int
Forum Allergy Rhinol, 2020.
125. Fokkens, W., P. Hellings, and C. Segboer, Capsaicin for
Rhinitis. Curr Allergy Asthma Rep, 2016. 16 (8): p. 60.
126. Halken, S., et al., EAACI guidelines on allergen
immunotherapy: Prevention of allergy. Pediatr Allergy Immunol, 2017.28 (8): p. 728-745.
127. Mitsias, D.I., et al., Immunotherapy in allergic diseases -
improved understanding and innovation for enhanced effectiveness. Curr
Opin Immunol, 2020. 66 : p. 1-8.
128. Durham, S.R., et al., Treatment effect of sublingual
immunotherapy tablets and pharmacotherapies for seasonal and perennial
allergic rhinitis: Pooled analyses. J Allergy Clin Immunol, 2016.138 (4): p. 1081-1088 e4.
129. Jutel, M., et al., Real-world evidence of subcutaneous
allergoid immunotherapy in house dust mite-induced allergic rhinitis and
asthma. Allergy, 2020.
130. Papadopoulos, N.G., et al., International consensus on (ICON)
pediatric asthma. Allergy, 2012. 67 (8): p. 976-97.
131. Pitsios, C., et al., Clinical contraindications to allergen
immunotherapy: an EAACI position paper. Allergy, 2015. 70 (8):
p. 897-909.
132. Pajno, G.B., et al., Prevention of new sensitizations in
asthmatic children monosensitized to house dust mite by specific
immunotherapy. A six-year follow-up study. Clin Exp Allergy, 2001.31 (9): p. 1392-7.
133. Lim, J.H., et al., Sublingual immunotherapy (SLIT) for house
dust mites does not prevent new allergen sensitization and bronchial
hyper-responsiveness in allergic rhinitis children. PLoS One, 2017.12 (8): p. e0182295.
134. Di Bona, D., et al., Efficacy of allergen immunotherapy in
reducing the likelihood of developing new allergen sensitizations: a
systematic review. Allergy, 2017. 72 (5): p. 691-704.
135. Zielen, S., et al., Sublingual immunotherapy provides
long-term relief in allergic rhinitis and reduces the risk of asthma: A
retrospective, real-world database analysis. Allergy, 2018.73 (1): p. 165-177.
136. Jacobsen, L., et al., Specific immunotherapy has long-term
preventive effect of seasonal and perennial asthma: 10-year follow-up on
the PAT study. Allergy, 2007. 62 (8): p. 943-8.
137. Valovirta, E., et al., Results from the 5-year SQ grass
sublingual immunotherapy tablet asthma prevention (GAP) trial in
children with grass pollen allergy. J Allergy Clin Immunol, 2018.141 (2): p. 529-538 e13.
138. Prokopakis, E.P., L. Kalogjera, and A.D. Karatzanis,Pediatric Severe Chronic Upper Airway Disease (P-SCUAD). Curr
Allergy Asthma Rep, 2015. 15 (12): p. 68.
139. Mathioudakis, A.G., et al., Research Priorities in Pediatric
Asthma: Results of a Global Survey of Multiple Stakeholder Groups by the
Pediatric Asthma in Real Life (PeARL) Think Tank. J Allergy Clin
Immunol Pract, 2020. 8 (6): p. 1953-1960.e9.